| Literature DB >> 33239899 |
Adela Chirita-Emandi1,2, Costela Lacrimioara Serban2,3, Corina Paul4,5, Nicoleta Andreescu1,2, Iulian Velea4,5, Alexandra Mihailescu1, Vlad Serafim1,6, Diana-Andreea Tiugan1, Paul Tutac1, Cristian Zimbru1,7, Maria Puiu1,2, Mihai Dinu Niculescu1,8.
Abstract
INTRODUCTION: Insulin resistance plays a major role in metabolic syndrome and is recognized as the most common risk factor for non-alcoholic fatty liver disease (NAFLD). Identifying predictors for insulin resistance could optimize screening and prevention.Entities:
Keywords: CHDH-PNPLA3; children; choline; gene–gene interaction; insulin-resistance; obesity
Year: 2020 PMID: 33239899 PMCID: PMC7682614 DOI: 10.2147/DMSO.S277268
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Descriptive Statistics (Mean ± SD) of Anthropometric, Biochemical and Intake-Related Variables in 153 Children with Obesity and Comparatively in Boys and Girls
| Variables Mean ± SD | Boys | Girls | All Children | p value | p value Insulin Resistance | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insulin Resistance | Insulin Resistance | Insulin Resistance | ||||||||||
| No (n=33) | Yes (n=47) | All Boys (n=80) | No (n=27) | Yes (n=46) | All Girls (n=73) | No (n=60) | Yes (n=93) | All (n=153) | ||||
| Anthropometric | Age (years) | 12.4 ± 3.5 | 11.5 ± 2.7 | 11.9 ± 3.1 | 12.8 ± 2.8 | 11.4 ± 3.0 | 12.0 ± 3.0 | 12.6 ± 3.2 | 11.5 ± 2.8 | 11.9 ± 3.0 | 0.493 * | 0.021 * |
| zBMI | 3.39 ± 0.84 | 3.91 ± 1.48 | 3.70 ± 1.28 | 2.61 ± 0.78 | 3.36 ± 1.05 | 3.08 ± 1.02 | 3.04 ± 0.90 | 3.64 ± 1.31 | 3.40 ± 1.20 | |||
| Waist to hip ratio | 0.98 ± 0.15 | 0.98 ± 0.06 | 0.98 ± 0.11 | 0.95 ± 0.11 | 0.95 ± 0.09 | 0.95 ±0.10 | 0.97 ± 0.13 | 0.97 ± 0.08 | 0.97 ± 0.10 | 0.199 ** | ||
| Metabolic | HOMA-IR | 2.2 ± 1.3 | 6.1 ± 3.2 | 4.5 ± 3.2 | 2.2 ± 1.2 | 5.8 ± 3.2 | 4.5 ± 3.2 | 2.2 ± 1.2 | 5.9 ± 3.2 | 4.5 ± 3.2 | 0.968 ** | |
| Cholesterol (mg/dl) | 171.1 ± 39.7 | 188.8 ± 49.5 | 181.5 ± 46.3 | 169.6 ± 36.2 | 170.0 ± 32.7 | 169.8 ± 33.8 | 170.4 ± 37.9 | 179.5 ± 42.9 | 175.9 ± 41.1 | 0.076 * | 0.184 * | |
| Triglycerides (mg/dl) | 128.5 ± 71.6 | 165.4 ± 80.3 | 150.1 ± 78.6 | 118.0 ± 56.8 | 148.7 ± 70.0 | 137.3 ± 66.7 | 123.8 ± 65.1 | 157.1 ± 75.4 | 144.0 ± 73.2 | 0.415 ** | ||
| HDL cholesterol (mg/dl) | 48.8 ± 11.0 | 50.7 ± 15.0 | 50.0 ± 13.4 | 50.7 ± 16.6 | 45.4 ± 10.9 | 47.4 ± 13.4 | 49.7 ± 3.7 | 48.1 ± 13.3 | 48.7 ± 13.5 | 0.074 ** | 0.408 ** | |
| AST (U/L) | 31.4 ± 9.1 | 37.7 ± 17.6 | 35.1 ± 15.0 | 29.2 ± 9.6 | 41.5 ± 46.9 | 36.9 ± 38.0 | 30.4 ± 9.3 | 39.6 ± 35.2 | 36.0 ± 28.3 | 0.222 ** | ||
| ALT (U/L) | 34.1 ± 16.6 | 45.5 ± 28.1 | 40.8 ± 24.6 | 28.6 ± 12.3 | 41.7 ± 36.6 | 36.9 ± 30.5 | 31.6 ± 15.0 | 43.6 ± 32.5 | 38.9 ± 27.6 | 0.106 ** | ||
| Choline (µmol/L) | 8.0 ± 2.5 | 9.4 ± 3.1 | 8.8 ± 2.9 | 7.5 ± 2.8 | 8.7 ± 2.8 | 8.2 ± 2.8 | 7.8 ± 2.6 | 9.1 ± 2.9 | 8.5 ± 2.9 | 0.211 * | ||
| Betaine (µmol/L) | 21.1 ± 11.6 | 22.2 ± 9.6 | 21.7 ± 10.4 | 21.9 ± 10.5 | 24.2 ± 10.3 | 23.3 ± 10.4 | 21.4 ± 11.0 | 23.2 ± 9.9 | 22.5 ± 10.4 | 0.347 * | 0.312 * | |
| ALA RBC (µmol/L) | 1.5 ± 0.7 | 2.1 ± 1.4 | 1.8 ± 1.2 | 1.4 ± 0.7 | 1.6 ± 0.8 | 1.5 ± 0.8 | 1.4 ± 0.7 | 1.8 ± 1.2 | 1.7 ± 1.0 | 0.064 ** | 0.080 ** | |
| DHA RBC (µmol/L) | 171.7 ± 73.7 | 197.8 ± 96.8 | 187.2 ± 88.6 | 168.5 ± 94.8 | 193.0 ± 158.9 | 183.9 ± 138.5 | 170.2 ± 83.3 | 195.4 ± 130.5 | 185.7 ± 114.9 | 0.324 ** | 0.325 ** | |
| LA RBC (µmol/L) | 217.0 ± 104.7 | 259.7 ± 113.8 | 242.4 ± 111.6 | 212.1 ± 90.0 | 220.5 ± 99.3 | 217.4 ± 95.4 | 214.8 ± 97.5 | 240.3 ± 108.1 | 230.4 ± 104.5 | 0.136 ** | 0.168 ** | |
| AR ARBC (µmol/L) | 348.1 ± 113.2 | 419.2 ± 179.6 | 390.4 ± 159.2 | 355.3 ± 165.1 | 374.9 ± 166.2 | 367.6 ± 164.9 | 351.4 ± 138.1 | 397.3 ± 173.6 | 379.5 ± 161.9 | 0.236 ** | 0.323 ** | |
| EPA RBC (µmol/L) | 3.1 ± 1.9 | 3.9 ± 2.2 | 3.6 ± 2.1 | 3.3 ± 2.2 | 4.0 ± 6.4 | 3.7 ± 5.3 | 3.2 ± 2.0 | 3.9 ± 4.8 | 3.7 ± 3.9 | 0.085 ** | 0.234 ** | |
| Intake related | Percentage of energy intake from carbohydrates | 46.1 ± 7.7 | 44.0 ± 8.2 | 44.9 ± 8.0 | 47.8 ± 6.2 | 46.6 ± 5.8 | 47.0 ± 5.9 | 46.9 ± 7.1 | 45.3 ± 7.2 | 45.9 ± 7.2 | 0.062 * | 0.172 * |
| Percentage of energy intake from fat | 31.4 ± 7.2 | 34.0 ± 7.0 | 32.9 ± 7.2 | 32.5 ± 5.8 | 32.1 ± 5.6 | 32.2 ± 5.6 | 31.9 ± 6.6 | 33.0 ± 6.4 | 32.6 ± 6.5 | 0.496 * | 0.291 * | |
| Fraction of energy intake from REE | 0.69 ± 0.26 | 0.72 ± 0.26 | 0.71 ± 0.26 | 0.64 ± 0.16 | 0.60 ± 0.16 | 0.61 ± 0.16 | 0.67 ± 0.22 | 0.66 ± 0.23 | 0.66 ± 0.22 | 0.575 ** | ||
Notes: *t-test, **Mann–Whitney test. All tests were adjusted for false discovery rate, p-values in bold denote statistical significance. Insulin resistance was defined: for boys ≤13 years old, if HOMA-IR >2.67; for boys > 13 years, if HOMA-IR > 5.22; for girls ≤11 years old, if HOMA-IR > 2.22; for girls > 11 years, if HOMA-IR > 3.82. See Materials and Method.
Abbreviations: zBMI, standardized body mass index (BMI) to account for age and gender; HOMA-IR, homeostatic model assessment for insulin resistance; HDL, high-density cholesterol; g, grams; mg, milligrams; µmol/L, micromoles/litre; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL cholesterol, high-density lipoprotein cholesterol; ALA, alfa-linolenic acid; ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; RBC, red blood cell membrane; REE, resting energy expenditure; SD, standard deviation; n, number.
Figure 1Distribution of HOMA-IR values depicted as boxplot separately for boys and girls, by age (rounded).
Notes: Horizontal lines, within each boxplot, indicate minimum, first quartile (Q1), median, third quartile (Q3), and maximum. Outliers marked with circles are cases with values between 1.5 and 3 times the IQ range, beyond the whiskers. Outliers marked with a star are cases with values more than 3 times the IQ range.
Description of Interaction Groups Formed by Genotypes in rs12676 in CHDH and rs738409 in PNPLA3 Gene to Predict Insulin Resistance Using the Gender and Puberty-Specific HOMA-IR Cut-Offs
| HOMA-IR Mean ± SD, n | rs12676 CHDH Gene | |||
|---|---|---|---|---|
| AA | AC | CC | ||
| rs738409 PNLAP3 gene | CC | High risk | Low risk | High risk |
| 5.8 ± 4.3 | 3.9 ± 2.1 | 4.1 ± 2.6 | ||
| n=7 | n=31 | n=41 | ||
| CG | High risk | High risk | Low risk | |
| 6.5 ± 3.1 | 6.8 ± 4.8 | 2.4 ± 2.0 | ||
| n=4 | n=11 | n=14 | ||
| GG | High risk | Low risk | High risk | |
| 6.2 ± 3.1 | 3.9 ± 2.6 | 5.7 ± 4.3 | ||
| n=6 | n=22 | n=17 | ||
Comparison Between Anthropometric, Biochemical and Intake-Related Variables in 153 Children with Obesity, Classified by the Interaction Between Rs12676 and Rs738409, to Predict High/Low Risk for Insulin Resistance Using the Gender and Puberty-Specific HOMA-IR Cut-Offs
| Variables Mean ± SD | Interaction Groups | p-values | ||
|---|---|---|---|---|
| Low Risk n=67 | High Risk n=86 | |||
| Anthropometric | Age (years) | 12.2 ± 3.1 | 11.7 ± 3.0 | 0.289 * |
| zBMI | 3.30 ± 0.94 | 3.49 ± 1.36 | 0.341 * | |
| Wait to hip ratio | 0.96 ± 0.09 | 0.98 ± 0.11 | 0.401 ** | |
| Metabolic | HOMA-IR | 3.6 ± 2.3 | 5.2 ± 3.6 | |
| Cholesterol (mg/dl) | 174.9 ± 41.0 | 176.7 ± 41.4 | 0.787 * | |
| Triglycerides (mg/dl) | 150.9 ± 84.2 | 138.7 ± 63.3 | 0.691 ** | |
| HDL cholesterol (mg/dl) | 46.3 ± 10.6 | 50.6 ± 15.1 | 0.200 ** | |
| AST (U/L) | 34.5 ± 15.0 | 37.1 ± 35.4 | 0.800 ** | |
| ALT (U/L) | 36.4 ± 18.9 | 40.9 ± 32.7 | 0.935 ** | |
| Choline (µmol/L) | 8.5 ± 2.9 | 8.6 ± 2.9 | 0.721 * | |
| Betaine (µmol/L) | 21.7 ± 10.3 | 23.1 ± 10.4 | 0.387 * | |
| ALA RBC (µmol/L) | 1.6 ± 0.8 | 1.7 ± 1.2 | 0.564 ** | |
| DHA RBC (µmol/L) | 176.4 ± 89.4 | 193.0 ± 131.6 | 0.589 ** | |
| LA RBC (µmol/L) | 221.9 ± 94.2 | 237.1 ± 112.1 | 0.605 ** | |
| ARA RBC (µmol/L) | 369.2 ± 150.6 | 387.5 ± 170.7 | 0.765 ** | |
| EPA RBC (µmol/L) | 3.3 ± 2.2 | 3.9 ± 4.9 | 0.187 ** | |
| Intake related | Percentage of energy intake from carbohydrates | 46.1 ± 7.3 | 45.7 ± 7.1 | 0.711 * |
| Percentage of energy intake from fat | 32.5 ± 6.4 | 32.6 ± 6.5 | 0.911 * | |
| Fraction of energy intake from REE | 0.66 ± 0.18 | 0.66 ± 0.25 | 0.932 * | |
Notes: *t-test, **Mann–Whitney test. All tests were adjusted for false discovery rate, p-values in bold denote statistical significance.
Abbreviations: zBMI, standardized body mass index (BMI) to account for age and gender; HOMA-IR, homeostatic model assessment for insulin resistance; HDL, high-density cholesterol; g, grams; mg, milligrams; µmol/L, micromoles/liter; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL cholesterol, high-density lipoprotein cholesterol; ALA, alfa-linolenic acid; ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; RBC, red blood cell membrane; SD, standard deviation; n, number of subjects in a group.